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Abstract
Aims: Posttranslational formation of disulfide bonds is essential for the folding of many secreted proteins. For-
mation of disulfide bonds in a protein with more than two cysteines is inherently fraught with error and can result in
incorrect disulfide bond pairing and, consequently, misfolded protein. Protein disulfide bond isomerases, such as
DsbC of Escherichia coli, can recognize mis-oxidized proteins and shuffle the disulfide bonds of the substrate
protein into their native folded state. Results: We have developed a simple blue/white screen that can detect
disulfide bond isomerization in vivo, using a mutant alkaline phosphatase (PhoA*) in E. coli. We utilized this screen
to isolate mutants of the sulfenic acid reductase (DsbG) that allowed this protein to act as a disulfide bond
isomerase. Characterization of the isolated mutants in vivo and in vitro allowed us to identify key amino acid
residues responsible for oxidoreductase properties of thioredoxin-like proteins such as DsbC or DsbG. Innovation
and Conclusions: Using these key residues, we also identified and characterized interesting environmental ho-
mologs of DsbG with novel properties, thus demonstrating the capacity of this screen to discover and elucidate
mechanistic details of in vivo disulfide bond isomerization. Antioxid. Redox Signal. 23, 945–957.
Introduction
Correct disulfide bond formation is essential for thefolding and stability of numerous secreted proteins (2).
As a result, cells have evolved dedicated enzymatic systems
that catalyze their formation and isomerization (8). Most of
these systems have thioredoxin-related thiodisulfide oxidore-
ductases (4). These proteins have various activities; thio-
redoxin serves mainly to reduce disulfides, DsbA to oxidize
cysteines to disulfides, DsbC to isomerize disulfides, andDsbG
to reduce sulfenic acid cysteine derivatives (6). Significant
progress has been made in understanding the sequence and
structural features that determine if a thioredoxin-related
protein serves to oxidize, reduce, or isomerize disulfide resi-
dues (18), but little is known what distinguishes disulfide
isomerases from proteins that are capable of sulfenic acid re-
duction.
DsbC, a homodimeric protein, has been shown in vivo and
in vitro (45) to be an effective disulfide bond isomerase, both
in the periplasmic (21) and cytoplasmic (20, 22) compart-
ments. DsbG is a periplasmic oxidoreductase that shares 27%
amino acid identity to DsbC. DsbG can function as a disulfide
isomerase, although it is considerably weaker than DsbC both
in vivo in facilitating the folding of urokinase (2) and in vitro
in catalyzing the isomerization of scrambled hirudin (12, 14).
In 2009, Depuydt et al. found that DsbG is a thiol protectant
in vivo, reducing single cysteines from overoxidation (6).
Recent studies have revealed that DsbC has a thiol protectant
activity very similar to DsbG, but with a different substrate
specificity (5).
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DsbC and DsbG exhibit similar activities under some con-
ditions and different activities under others, depending on the
substrate protein used in the study. For example, similar to
DsbC, DsbG also has in vitro chaperone activity (36) and can
assist in the folding of proteins in vivo when overexpressed (2,
49). Despite these similarities, these proteins have different
capacities to protect cells against copper toxicity. Copper is a
nonspecific thiol oxidant that catalyzes the formation of non-
specific non-native disulfide bonds in cells (30) resulting in
cellular toxicity. The disulfide bond reductase/isomerase
pathway is required to repair the oxidative damage caused by
copper, presumably through reducing and removing non-na-
tive disulfide bonds and/or rearranging non-native disulfide
bonds (13). Unlike DsbC, DsbG cannot protect cells against
copper cytotoxicity. Previously, the copper-sensitive pheno-
type of dsbC null mutants was used to select mutations in the
sulfenic acid reductase DsbG that conferred copper resistance
(13). Numerous other structural differences exist, comparing
DsbC and DsbG, and it is very difficult to determine just by
inspectionwhich of thesemultiple differences between the two
proteins are responsible for the differences in activity.
In this study, we demonstrate the use of a simple blue/white
screen capable of directly detecting disulfide bond isomeri-
zation in vivo. Unlike the previous screen based on isolating
mutants of DsbG that alleviated a general copper-induced
oxidative stress, in this article we present a new screen based
on the folding of amutant PhoA. Using this screen, we identify
key residues that enhance the isomerase activity ofDsbG in the
cell, deepening our in vivo understanding of how disulfide
bond isomerization enzymatic activity is determined.
Results
Detection of in vivo periplasmic disulfide bond
isomerase activity, using mutant PhoA*
We decided it would be useful to probe the in vivo
mechanism of disulfide bond isomerization using a mis-
oxidized protein, a mutant of periplasmic alkaline phospha-
tase. This mutant, PhoA*, lacks the first cysteine normally
present in PhoA (C168S) and also contains an aberrant cys-
teine (S410C). Unlike for wild-type (wt) PhoA, correct dis-
ulfide bond formation in PhoA* requires linking cysteines
that are nonconsecutive in sequence. PhoA* is initially mis-
oxidized by the oxidase DsbA, which preferentially links
consecutive cysteines. Its activity and folded state thus re-
quire the corrective action of the disulfide isomerase DsbC
for proper folding (40). DsbG cannot catalyze the correct
folding of PhoA*. This allows us to screen a plasmid library
of DsbG* mutants for those that have gained the ability to
fold PhoA* (39–41) (Fig. 1).
To confirm the dependence of PhoA* on DsbC for its
activity, we cloned the gene encoding for phoA* or wt
phoA into the expression vector pBAD33. To avoid in-
terference from chromosomally encoded alkaline phos-
phatase, all the strains used for the screen are phoA
minus. We expressed the two proteins in strains lacking
both the reductive pathway (dsbC/dsbD) and the oxida-
tive pathway (dsbA/dsbB), in a single and pairwise man-
ner, and measured the alkaline phosphatase activity from
cell lysates by measuring hydrolysis of 4-nitrophenyl
phosphate (pNPP) at 410 nm. As expected, wt PhoA was
active when expressed in cells lacking the reductive/
isomerase pathway (dsbC and/or dsbD) (Supplementary
Fig. S1A; Supplementary Data are available online at
www.liebertpub.com/ars). We also confirmed that PhoA*
is *5-fold less active than wt PhoA and is inactive when
expressed in cells lacking the reductive/isomerase path-
ways (Supplementary Fig. S1B). Interestingly, wt PhoA is
significantly more active in the DdsbD strain background,
most likely due to increased levels of oxidized DsbC en-
hancing the capacity of the cells to correctly oxidize PhoA.
Both PhoA constructs are inactive when expressed in cells
lacking the oxidative pathway (dsbA and/or dsbB).
The dependence of PhoA* on the dsbC/dsbD pathway
indicated that the homolog of DsbC and DsbG is not suffi-
cient to allow for the isomerization of disulfide bonds in
PhoA*. DsbG is normally expressed at a level only 20% of
that of DsbC (51, 52). To test whether overexpressed DsbG
can assist in the folding of PhoA*, we cloned dsbG into a
multicopy expression vector, pMER79 (38). The native sig-
nal sequence of dsbG on this plasmid was replaced with that
of the signal recognition particle (SRP)-dependent signal
sequence of torT (34) along with a 3¢ flag tag sequence. By
replacing the sec-dependent signal peptide of DsbG with that
of an SRP-dependent signal peptide of DsbA, we hoped to
circumvent mutations that may alter the secretion of DsbG*.
To monitor the folding and expression of PhoA* in the
presence of overexpressed DsbC or DsbG, we transformed
cells lacking dsbC and harboring pBAD33-phoA* with the
following: (i) an empty expression control vector, (ii) the
vector expressing dsbC, or (iii) the vector expressing dsbG-
flag. We grew the three strains on minimal agar plates that
contain 5-bromo-4-chloro-3-indolyl phosphate (XP), which
is an artificial substrate of PhoA. Strains that can hydrolyze
XP form blue colonies, whereas strains that cannot, form
opaque ecru colonies. Extensive optimization of each media
component and expression condition was required to achieve
the ideal time to detect the difference between blue and ecru
colonies (Supplementary Fig. S2).
We found that cells expressing DsbC formed blue colo-
nies, indicating that the PhoA* was functional. In contrast,
cells expressing DsbG-flag or the empty vector formed opa-
que ecru colonies, indicating that DsbG-Flag cannot func-
tionally substitute for DsbC to fold PhoA*, even when
overexpressed from a multicopy plasmid.
Selection of mutant DsbG* capable of folding PhoA*
The inability of DsbG to isomerize PhoA* allowed us to
use this as a screen to identify DsbG variants (designated
DsbG*) that can fold PhoA*. We transformed DdsbC DphoA
cells expressing PhoA* (MB1045) with a plasmid library of
dsbG* mutants. We screened a total of 30,000 transformants
on 3-(N-morpholino)propanesulfonic acid (MOPS)-XP
plates after incubation for 2 days at 30C. The phenotypes of
Innovation
Using these key residues, we also identified and char-
acterized interesting environmental homologs of DsbG
with novel properties, thus demonstrating the capacity of
this screen to discover and elucidate mechanistic details of
in vivo disulfide bond isomerization.
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small faint-blue colonies were confirmed by restreaking on
MOPS-XP plates. Plasmid DNA from the positive clones was
transformed into a dsbC, dsbG null strain expressing phoA*
(MB2272) to confirm that the blue colony phenotype was
linked to the plasmid and not the host strain. From the 48
dsbG* candidates sequenced, we recloned 18 of them into the
parental vector to avoid any plasmid backbone-linked pheno-
type and then resequenced them. The final 18 mutant dsbG*
candidates identified are listed in Supplementary Table S1.
The DsbG structure is composed of a thioredoxin-like
domain connected to a dimerization domain through a 24
amino acid linker. We mapped the location of the mutations
to each of these three domains of DsbG. We analyzed the
change in charge, which occurred due to the mutation, to
evaluate whether the mutations increased or decreased the
charge in the cleft between the two monomers of DsbG (the
cleft in DsbG is more charged compared with DsbC). Finally,
we analyzed each mutation using the web-based ConSurf
software, which measures the degree to which a residue is
conserved among both DsbC and DsbG homologs as a way to
first gauge how important that residue is to the structure and/
or function of the combined DsbC/G isomerase family and
then to separately gauge how conserved it was within the
individual DsbC and DsbG families.
To confirm that the DsbG* mutants can fold PhoA*, we
conducted alkaline phosphatase assays on cells express-
ing both PhoA* and the selected 18 DsbG* candidates
(Supplementary Fig. S3). As expected, the strain expressing
DsbC was able to correctly fold PhoA*, resulting in high
alkaline phosphatase activity. Ten of the dsbG* candidates
carried single mutations and 8 carried two to six mutations,
with an overall average of 2.2 amino acid substitutions per
dsbG* gene. For those that contained single substitutions, we
can be reasonably certain that these mutations are sufficient
to confirm the increased PhoA* activity. For those that con-
tained multiple mutations, the individual mutations could all
contribute in an additive manner or some of these mutations
could be silent or partially deleterious. The three DsbG var-
iant strains that expressed the highest level of PhoA* con-
tained three to six mutations suggesting that in these cases
more than one mutation may contribute to their strong phe-
notype. Interestingly, several of the residues mutated in our
selection (K113N, N198I, and T211S) had been previously
found using the copper selection (K113E/N, N198Y/I, and
FIG. 1. Principle of in vivo disulfide bond isomerase screen using mutant PhoA*. (A) ¿ Reduced wt alkaline phos-
phatase (wt PhoARED) with four cysteines (yellow balls with numbers indicating cysteine residue) is correctly oxidized by
DsbA to form two consecutive disulfide bonds. ¡ Active folded PhoA (wt PhoAOXI) can hydrolyze XP, Æ resulting in blue
colonies. Ø Reduced mutant alkaline phosphatase (PhoA*RED) lacking the first cysteine (C168A) and with an additional
mutant cysteine (S410C inmagenta) is mis-oxidized by DsbA (PhoA*MIS-OXI), resulting in unknown disulfide bond pattern.ƒ
Colonies expressing inactive misfolded PhoA*, which cannot hydrolyze XP, remain their natural white color. ± Misfolded
PhoA* is isomerized by DsbC or DsbG* mutants to an active form (PhoA*OXI) with an unknown disulfide bond pattern
resulting in blue colonies. (B) Selection of DsbG* mutants on MOPS-XP plates. ¿ Cells lacking dsbC, dsbG, phoA and
harboring an empty expression vector along with pBAD33-PhoA* are opaque and ecru when plated on the selective MOPS-
XP media.¡ Cells turn blue when expressing DsbC from the plasmid pDSW204.Æ Cells remain ecru when expressing DsbG
from the plasmid pMER79. Ø PCR mutagenized library of pMER79-dsbG*-flag, transformed into cells lacking dsbC, dsbG,
phoA, and blue colonies, which have active folded PhoA*, was selected. MOPS, 3-(N-morpholino)propanesulfonic acid; PCR,
polymerase chain reaction; wt, wild type; XP, 5-bromo-4-chloro-3-indolyl phosphate.
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T211R/M) (14) (see Introduction section). K113N, for in-
stance, was present in the DsbG variant that conferred the
second highest level of PhoA* activity and also had been
isolated multiple times as copper-resistant mutations. How-
ever, the remainder of the DsbG* variants isolated with the
PhoA* screen was different from those isolated through
copper resistance, suggesting that the two procedures se-
lected for at least slightly different activities. Expression of
DsbG* variants resulted in PhoA* activity up to 70% of that
found in strains wild type for DsbC, suggesting that we had
obtained DsbG variants that could effectively replace DsbC
(Supplementary Fig. S3A). Surprisingly, while the entire
mutant DsbG*s selected and retransformed were confirmed
to be bluer than wt DsbG, expression of five mutants resulted
in PhoA* activities that were close to or below the levels
observed with wt DsbG. Although these results suggest that
the PhoA* selection scheme results in few false positives, the
use of two different substrates, XP and pNPP, for the analysis
of activity in solid versus liquid media may explain the dif-
ferences in the PhoA* activity and/or folding.
To evaluate whether the 18 DsbG* mutants were specific to
folding only PhoA* or if they were also capable of folding
other proteins that required disulfide isomerization, we trans-
formed DdsbC cells expressing phytase (appA) with each of
the 18 dsbG* plasmids. AppA is an Escherichia coli peri-
plasmic enzyme containing three consecutive and one non-
consecutive disulfide bond. Folding of AppA is dependent on
the disulfide bond isomerase activity of DsbC (1). However,
the folding of AppA is not specific to DsbC, as AppA can fold
efficiently (*90%) when wt DsbG is overexpressed. Expres-
sion of the 18 dsbG* plasmids generally resulted in 60–90%
AppA activity, indicating that nearly all of the DsbG* variants
are still proficient in folding of AppA and have, therefore, not
lost their isomerase/chaperone function (Supplementary Fig.
S3B). The only apparent exception was DsbG*63, which
complemented the folding of AppA at levels only 40% that of
DsbC (Supplementary Fig. S3B, lane 6).
A single-point mutation in DsbG* is sufficient to gain
the ability to facilitate the folding of PhoA*
The initial screen on MOPS-XP plates identified many
DsbG* mutants capable of folding PhoA*. We selected three
DsbG* mutants (DsbG*2, DsbG*50, and DsbG*72) for further
characterization, as their expression either resulted in the
greatest improvements in the folding of PhoA* (85%DsbG*2,
75% DsbG*50 activity in relation to DsbC) (Fig. 2B) or was
potent in the ability of DsbG to rescue from copper toxicity
(DsbG*72 protection against copper was equal to DsbC) (Fig.
2C). These mutants carried multiple amino acid substitutions
(DsbG*2: L43Q, K113N, Q214R; DsbG*50: A5S, K8T, F21L,
L169P, D193G, Q214R; and DsbG*72: K19R, T44S, Y56F,
V199A, T211S). To identify critical residues involved in dis-
ulfide bond isomerization, we engineered 13 DsbG* mutants,
each having one of the mutations from the three selected
mutants. We were particularly interested in two of these mu-
tations: (i) Q214R because it was present both in DsbG*2 and
DsbG*50 and (ii) K113N because it was present in DsbG*2 and
had previously been shown to be effective in allowingDsbG to
confer protection against copper toxicity (14).
To evaluate the in vivo disulfide bond isomerase activity of
the three selected mutants (DsbG*50, DsbG*2, and DsbG*72)
and the engineered 14 DsbG* mutants with single amino acid
substitutions, the PhoA* activity was determined from crude
lysates of DdsbC DdsbG cells expressing PhoA* and various
DsbG*mutants (Fig. 2A). Strains expressingmost of themutant
DsbG*s showed a PhoA* activity equal to or higher compared
with a strain overexpressing wt DsbG. Strains expressing
DsbG*50 and DsbG*2 displayed the highest PhoA* activity,
while the strain expressing DsbG*72, which confers a high level
FIG. 2. In vivo activities of DsbG* mutants. Cells ex-
pressing PhoA* or RNase I from pBAD33 and DsbC/DsbG/
DsbG* from pMER79 were grown in M63 minimal media
until mid-log phase. All activities were normalized to cells
expressing DsbC. Control constructs (lanes 1–3, black
bars), selected DsbG* mutants (lanes 4–6, dark gray bars),
and engineered DsbG* mutants (lanes 7–20, light gray bars)
are indicated. (A) In vivo alkaline phosphatase activity.
Phosphatase activities from whole cells were measured as an
increase in the rate of absorbance at 410 nm, using pNPP.
(B) In vivo RNase activity. RNase activities from soluble
lysates were measured as a decrease in the rate of absor-
bance at 688 nm, in a methylene blue assay. (C) In vivo
copper toxicity protection. Cells were serially diluted,
spotted on BHI plates supplemented with 9mM CuSO4, and
grown for 2 days at 30C. BHI, brain heart infusion; pNPP,
4-nitrophenyl phosphate; RNase I, ribonuclease I.
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of copper resistance, showed a PhoA* activity of only 11%. Of
the engineered single mutants, expression of DsbG*Q214R re-
sulted in an eightfold higher PhoA* activity compared to wt
DsbG, while expression of DsbG*K113N resulted only in a
twofold improvement. However, this mutant still remained
lower than the original multimutant parental DsbG* (DsbG*50
and DsbG*2), suggesting multiple mutations are necessary to
convert DsbG into an efficient disulfide bond isomerase that is
capable of folding PhoA*.Nevertheless, a single-pointmutation
Q214R in DsbG is sufficient to make the enzyme partially able
to fold PhoA* (Fig. 2A, lane 8) into its native active structure.
This effect was further enhanced with the addition of the critical
K113Nmutation, resulting in a double mutant named DsbG*KQ
(Fig. 2A, lane 7).
DsbG* mutants can assist folding ribonuclease I,
a native substrate of DsbC
The DsbG* mutants were selected for their ability to fold
the artificial DsbC substrate PhoA*. It is conceivable that
mutations are specific to folding PhoA* and have not con-
verted DsbG* to a general disulfide bond isomerase. To
evaluate the substrate specificity of the selected DsbG*s, we
performed a third in vivo disulfide bond isomerase activity
assay using a natural substrate of DsbC, ribonuclease I
(RNase I). E. coli periplasmic RNase I contains four disulfide
bonds, including a nonconsecutive one, making its folding
dependent on DsbC (12, 26). To evaluate the disulfide bond
isomerase activity of DsbG* mutants, we used a methylene
blue assay to measure RNase I activity from lysates made
from DdsbC DdsbG cells overexpressing periplasmic RNase
I as well as various DsbG* mutants (Fig. 2B).
The RNase I activity in cells overexpressing wt DsbG from a
plasmid was 5%, barely above cells with an empty vector (3%),
whereas overexpression of DsbC was sufficient to restore the
RNase I activity (100%). Overexpression of all DsbG* mutants
resulted in a significant increase in RNase I folding, although
these activities, which ranged from 15% to 70%, did not reach
the 100% level found in the strain overexpressing DsbC. These
results indicate that the selected mutations in DsbG* obtained
from the PhoA* screen confer a general disulfide bond isom-
erization activity; they are not specific for the ability to fold only
the artificial DsbC substrate PhoA*, but can also assist in the
folding of a natural substrate, RNase I.
DsbG* mutants confer protection
against copper cytotoxicity
Previously, the copper-sensitive phenotype of dsbC null
mutants was used to select mutations in DsbG that conferred
copper resistance (13). A number of these copper-resistant
DsbG mutants showed enhanced isomerase activity. Inter-
estingly, several of the residues mutated in our selection
(K113E/N, N198Y/I, and T211R/M) had been previously
found in this copper resistance selection (K113N, N198I, and
T211S) (14). K113N, for instance, was present in the DsbG
variant that conferred the second highest level of PhoA* ac-
tivity and also had been isolated multiple times as copper-
resistant mutations. However, the remainder of the DsbG*
variants isolated with the PhoA* screen was different from
those isolated through copper resistance, suggesting that the
two procedures were selected for at least slightly different
activities. To further evaluate the in vivo disulfide bond re-
ductase/isomerase activity of theDsbG*mutants isolatedwith
the PhoA* screen, we plated out serial dilutions of DdsbC
DdsbG cells harboring various DsbGmutants in minimalM63
media and plated them out in serial dilutions on brain heart
infusion (BHI) agar plates supplemented with 9mM copper.
We compared the growth of strains harboring DsbG* mutants
to strains with wt DsbG or DsbC (Fig. 2C). As expected, cells
overexpressing DsbC grew in the presence of copper, whereas
cells overexpressing wt DsbG or containing an empty vector
did not. Two of our 18 DsbG*-selected mutants (DsbG*2 and
DsbG*72) protected cells at significant levels from copper
toxicity. Not surprisingly, these mutants contained residues
that whenmutated had previously been shown to cause copper
resistance (Supplementary Fig. S4).
Among these two DsbG* mutants, only DsbG*72 (Fig. 2C,
lane 6) provided full protection against copper toxicity similar to
DsbC. Partial protection was observed for DsbG*2 and for the
engineered DsbG*K113N and DsbG*Y56F (Fig. 2C, lane 5, 9, and
14). Both DsbG*K113N and DsbG*2 contain mutations previ-
ously associated with copper resistance, but DsbG*Y56F does
not. Interestingly, expression of the engineered double mutant
DsbG*KQ further enhanced the copper protection capacity of
DsbG*K113N and resulted in DsbC-like copper toxicity protec-
tion. Surprisingly, DsbG*V199A provided full protection against
copper toxicity (Fig. 2C, lane 18) compared to partial protection
by DsbG*K113N, which had previously been selected specifi-
cally for copper toxicity protection (13). The copper-resistant
mutants were selected to alleviate general overoxidation in the
periplasm and not to fold and isomerize a specific protein.
In conclusion, our screen identified new DsbG mutations
that confer general capacity to protect cells against copper-
inducedmis-oxidation and fold mis-oxidized proteins that are
not specific to folding PhoA*. The additional mutations
isolated in our screen indicate that the mutant landscape of
DsbG was wider than previously appreciated.
Key residues identified in PhoA* screen can help
discover DsbG homologs with novel properties
The PhoA* screen identified several residues important in
modulating the redox activities of DsbG. Homologs having
the same substitutions that could, in theory, exist in nature,
and the amino acid substitutions identified in our screen could
represent the functional and biological diversity of DsbC/G-
like proteins. To test this hypothesis, we analyzed DsbC and
DsbG homologs identified in sequenced bacterial genomes
and asked whether any homolog contained any of the three
key residues (N113, R214, and A199) identified in the PhoA*
screen. We used a hidden Markov model to predict which of
the *390 homologs (Supplementary Table S2) were DsbC
like or DsbG like and conducted further characterization on
the topology, active site, and phylogeny of the homologs
(Supplementary Fig. S5). Using this list, we searched for
homologs of DsbG that naturally contained residues identi-
fied in our screen to be critical (Supplementary Table S3).
We found a homolog of DsbG in Thiobacillus denitrificans
ATCC 25259 that contained the key residue N113, shown to
confer protection against copper toxicity in DsbG*K113N
(Supplementary Fig. S6A). T. denitrificans also has been
previously identified to be resistant to copper and has been
used in bioremediation for the removal of metals (42). We
therefore postulated that unlike E. coli DsbG (DsbGEc), since
CONVERTING DSBG TO DSBC 949
the T. denitrificans DsbG (DsbGTd) has an N at the key 113th
residue, its residue should confer copper resistance and be
able to fold PhoA*. We performed alkaline phosphatase ac-
tivity and copper protection assays with DdsbC DdsbG
DphoA E. coli cells expressing PhoA* along with DsbGTd,
DsbGEc, DsbG*K113N, or DsbG*KQ. DsbGTd gave higher
PhoA* activity compared to DsbG*K113N and equal to
DsbG*KQ (Supplementary Fig. S6B). As predicted, DsbGTd,
DsbG*K113N, and DsbG*KQ provided similar levels of pro-
tection against copper toxicity (Supplementary Fig. S6C).
These results indicate that key residues identified in modu-
lating DsbG activity can be used to discover oxidoreductases
with novel properties. We postulate that the N113mutation in
DsbGTd could contribute, at least in part, to the ability of
T. denitrificans to resist copper. Our identification of key
residues that appear to modulate the DsbG activity may be
useful in predicting the property of DsbG homologs.
In vitro oxidoreductase properties of DsbG* mutants
The DsbG* mutants isolated from the PhoA* screen have
significant differences in their in vivo substrate specificity and
in their capacity to protect cells from copper toxicity. To
further our understanding on the effects of the mutations on
DsbG’s oxidoreductase properties, we compared the in vitro
redox activities of purified DsbG* mutants to wt DsbG and
DsbC. We focused our studies on the original screen mutants,
DsbG*2, DsbG*50, and DsbG*72, and on the engineered mu-
tants, DsbG*KQ, DsbG*Q214R, DsbG*K113N, and DsbG*V199A.
We performed three different in vitro assays to biochemically
characterize their capacities to (i) reduce disulfide bonds, (ii)
oxidize cysteines, and (iii) isomerize incorrect disulfide bonds
(Fig. 3).
In our first biochemical assay, we assayed the ability of
DsbG* mutants to reduce disulfide bonds using an insulin re-
ductase assay. We found that DsbG and its variants have neg-
ligible insulin reductase activity in vitro,*1000-fold less than
DsbC (Fig. 3A). We conclude that the DsbG* mutants like wt
DsbG function very poorly as disulfide bond reductases in vitro.
In the second biochemical assay, we determined the ability
of the mutants to oxidize cysteines by conducting hirudin
oxidase assays. We monitored oxidation of fully reduced
hirudin by DsbG and its variants in vitro by fluorescence
excitation at 295 nm, which increases when oxidized DsbG
FIG. 3. In vitro activities of DsbG* mutants. Purified
DsbC/DsbG/DsbG* samples were subjected to various
in vitro assays. Negative control samples without protein, wt
DsbC and wt DsbG control samples are shown as black bars
(lanes 1–3). Selected DsbG* mutants (lanes 4–6, dark gray
bars) and engineered DsbG* mutants (lanes 7–10, light gray
bars) are indicated. (A) Disulfide bond reductase activity.
Protein samples were incubated with disulfide-bonded in-
sulin and the rate of its reduction was followed at 650 nm in
the presence of DTT. (B) Disulfide bond oxidase activity.
Protein samples were incubated with fully reduced hirudin
and the increase in DsbG fluorescence excitation at 295 nm
was monitored over time. (C) Disulfide bond isomerase
activity. Protein samples were incubated with scrambled
hirudin and the folding of correctly folded hirudin was
measured by HPLC. Horizontal gray bar indicates level of
activity observed for wt DsbG. DTT, dithiothreitol; HPLC,
high-performance liquid chromatography.
‰
950 CHATELLE ET AL.
donates its disulfide bond to hirudin. DsbC-catalyzed hirudin
oxidation cannot be measured because the tryptophan fluo-
rescence of DsbC does not correlate with its active-site dis-
ulfide bond redox status (47). Our results indicate that neither
wt DsbG nor the vast majority of DsbG* variants can effi-
ciently catalyze the oxidation of hirudin in vitro (Fig. 3B).
The only exception was DsbG*V199A, which displayed a
significant (*5-fold) more rapid change in fluorescence
compared to wt DsbG, when incubated with reduced hirudin
(Fig. 3B, lane 10).
The in vitro oxidase activity of DsbG*V199A indicated that
perhaps the in vivo folding of PhoA* is due to its correct
oxidation by DsbG*V199A, before its mis-oxidation by DsbA.
To test the hypothesis that the DsbG* mutants could properly
oxidize and fold PhoA* in the absence of both DsbA and
DsbC, we grew DdsbC DdsbA cells expressing PhoA*
along with the selected DsbG* variants in minimal media
and assayed the phosphatase activity from whole cells
(Supplementary Fig. S7). Expression of DsbG* mutants re-
sulted in a significantly higher activity of PhoA* compared to
the background oxidation of cells expressing wt DsbG from
the same vector (Supplementary Fig. S7, lane 3). The only
exception was DsbG*72, which did not, however, it was not
isolated for an ability to fold PhoA*, but rather for its ability
to protect cells against copper-induced toxicity. Notably,
none of the DsbG*mutants was as efficient as wt cells (dsbA+
dsbC+) in expressing PhoA* in vivo (Supplementary Fig. S7,
lane 1). This indicates that DsbG* alone is insufficient for the
correct folding of PhoA*.
In our third biochemical assay, we determined whether the
purified DsbG* mutants could isomerize disulfide bonds
in vitro by incubating equal molar quantities of scrambled
hirudin and purified DsbG and variants. We quenched the
reaction by acid and quantified the amount of correctly folded
hirudin using high-performance liquid chromatography
(HPLC) (Fig. 3C). In the absence of any added disulfide
oxidoreductase, we found that*30% of the hirudin had at-
tained its correctly folded state (Fig. 3C, lane 1). Upon in-
cubation with DsbC, we detected almost all of the scrambled
hirudin in its correctly folded state, compared to only*60%
in its correctly folded state when incubated with wt DsbG
(Fig. 3C, lane 2 and 3). The majority of the DsbG* mutants
appeared to improve the folding of hirudin slightly, compared
to wt DsbG (ranging from*75% to*95%). Only mutants
FIG. 4. Structural locations of mu-
tations isolated in DsbG*. (A) DsbG
homodimer is shown with the thior-
edoxin (blue) and dimerization ( pur-
ple) domains highlighted. The alpha-
helical linker is shown in gray. The
locations of the three substitutions (red)
are shown in each dimer with arrows.
(B) Close-up structures of the wt DsbC
and DsbG and the modeled DsbG* are
shown. PyMOL predicted structures of
mutant residues ( purple), and wt resi-
dues (black) are shown. The active site
cysteines are shown as yellow balls and
the resolving (R) and attacking (A)
cysteines are indicated.
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DsbG*50 and DsbG*Q214R did not show any improvement in
their capacity to isomerize scrambled hirudin.
Structural analysis of the DsbG* mutants
(K113N, V199A, Q214R)
We mapped the three mutations Q214R, K113N, V199A
that we identified as being critical for the modulation of DsbG
isomerase activity on the crystal structure of DsbG (PDB#
1V58) (11) and conducted in silico modeling of the substi-
tutions using PyMOL (35). Both V199 and K113 are in close
proximity to the active site C109XXC112, while Q214 is fac-
ing the cleft formed between the two subunits of DsbG (Fig.
4A). The alignment between modeling output and crystal
structures results in a RMSD of 0.62 A˚ with none of the
substitutions significantly affecting the overall fold.
DsbGK113N. Modeling of the K113N substitution pre-
dicted that the hydrogen bond network involving a water
molecule stabilized by K113 and E163 in wild-type DsbG is
retained in DsbGK113N (Fig. 4B). However, the shorter as-
paragine side chain creates a small cleft exposing the charge of
the E163 carboxyl group. A short 0.1 ns dynamics simulation
(data not shown) suggests that the solvent can enter this cavity
and disturb the E163-H2O-N113 hydrogen bond network.
These residues are located near the resolving active site C112
and could be involved in electron/proton transfers between the
solvent and the buried C112 in the active site. It has been
previously shown that the ionizable residues in a buried en-
vironment can impact cysteine pKa values and, thus, affect
cysteine reactivity (7). Replacing the ionizable K113 with a
polar, uncharged asparagine residue could modify the physi-
cochemical properties of the environment surrounding the
CXXC active site. In DsbC, this environment is mainly com-
posed of hydrophobic residues (the E163-H2O-K113 bridge
position is occupied byMET153 eCH3). Thus, we assume that
K113N mutation in DsbG could modify the CXXC activity in
a DsbC-like way. This could explain the enhancement in
DsbGK113N in vitro reductase activity and its improved ca-
pacity to protect against copper-induced cytotoxicity.
DsbGV199A. The V119A substitution occurs on the loop
that contains the highly conserved cis-proline 201, known to
play a critical role in the activity and substrate release ki-
netics of oxidoreductases (19, 29). The modeling result
suggests that V199A substitution adopts the same orientation
as in wt DsbG and is in the -2 position in relation to the cis-
P201. The V199A substitution lowers steric contacts between
the cis-proline loop and surrounding amino acids, enhancing
the flexibility of this loop in a DsbC-like manner. This in-
creased flexibility would change the P201 dynamics, in direct
contact with the resolving cysteine in the CXXC active site.
Similar observations have been made for mutations in the -1
position of the cis-proline, which modulate the oxidoreduc-
tase properties of thioredoxin (24, 29). In DsbC, DsbA, and
TrxA, a glycine residue occupies the equivalent -2 position.
Our observations are the first example of a mutation that
modulates the activity of an oxidoreductase, in the -2 position
of the critical cis-proline 201.
DsbGQ214R. Unlike K113N and V199A, the Q214R
substitution is distant from the CXXC active site and is lo-
cated at the surface of the DsbG cleft. The modeling suggests
that the R214 guanidium group interacts (by hydrogen/ion–
dipole interaction) with L195 backbone oxygen, in the C-
terminus of helix a3, significantly diminishing the strength of
the hydrogen bond (from wt = 3 A˚ to mutant Q214R = 3.3 A˚).
In DsbC, the Q214 position in DsbG is occupied by L192
that forms a hydrophobic cluster with L177 and a V179 in
C-terminus of helix a3 (Fig. 4). We propose that the arginine
side chain (longer than glutamine and composed of three
aliphatic uncharged carbons) enlarges the hydrophobic
surface of the DsbG cleft. This would modify the DsbG-
substrate interaction and could enhance the ability of
DsbGQ214R to recognize different unfolded proteins, as is the
case for DsbC.
Taken together, the substitutions with profound effects on
DsbG’s activity are all predicted to weaken the intramolecular
bonds within DsbG, especially around its active site.
Discussion
In this study, we introduce the use of a new yet simple blue/
white genetic screen that can detect the disulfide bond
isomerase activity in vivo. This screen is based on a seren-
dipitously discovered mutant of alkaline phosphatase PhoA*
that is dependent on DsbC for its folding and activity. We
have used this screen to identify key residues involved in
converting the sulfenic acid reductase DsbG into a disulfide
bond isomerase that can rescue the isomerase defects in DsbC
null mutants.
DsbC and DsbG are homologous proteins that are similar
both in their structure and function. Their high level of
similarities not surprisingly results in significant overlap in
activities, yet they are sufficiently divergent as to have dif-
ferent substrate specificities. Overexpression of DsbG in vivo
results in the correct folding of AppA and P1Lys (44) (data
not shown), but not PhoA* or RNase I. On the other hand,
DsbC is thought to assist in the folding of all the native E. coli
substrates having nonconsecutive disulfide bonds and many
eukaryotic proteins that are expressed recombinantly, sug-
gesting significant functional differences between DsbC and
DsbG. These differences in their substrate specificity may be
due to differences in their CXXC active site pocket (27),
known to modulate the activities of oxidoreductases (25).
The active site residue K113 identified previously (14) and in
our PhoA* screen here, along with the newly identified
V199A, appears to be such a substitution modulating the
activity of disulfide bond isomerases. Another difference
between DsbC and DsbG is the electrostatic and structural
make-up of their clefts. It has been assumed that the larger
more charged cleft of DsbG plays a crucial role in modulating
its activity and substrate specificity.
Through analyses of engineered DsbG* mutants with
single amino acid substitutions, we discovered three muta-
tions (Q214R, K113N, V199A) with profound effects on the
activities of DsbG. These mutations are likely conferring
isomerase activity on DsbG by either affecting DsbG-
substrate interaction or DsbG active site reactivity. The
substitution of glutamine 214 to arginine (Q214R) was suf-
ficient to confer to DsbG* 50% of DsbC’s ability to fold
PhoA*. Glutamine 214 resides in the cleft of DsbG, assumed
to be important in DsbG-substrate protein interaction. Com-
puter modeling using PyMOL predicted that the longer side
952 CHATELLE ET AL.
chain of arginine would result in steric hindrance, causing the
side chain of arginine to protrude into the cleft, likely af-
fecting DsbG interaction with its substrate protein. The
substitutions V199A and K113N are in close proximity to the
CXXC active site, with K113 having direct hydrogen bond-
ing with the active site cysteine 109, known to be involved in
deprotonation of the resolving cysteine (31).
With certain substrates, DsbC can become engaged in a
futile complex with a mis-oxidized protein that it cannot
isomerize. When this occurs, DsbC requires an escape reac-
tion. Otherwise, functional DsbC will be titrated out of the
periplasmic space and new DsbC will need to be synthesized.
DsbC can accomplish this escape reaction by reducing (in-
stead of isomerizing) the mis-oxidized substrate, resulting in
reduced substrate and oxidized DsbC. This may partially
explain why DsbD is required to maintain DsbC in its active
reduced state. These two models are not exclusive and are
likely to coexist. In fact, correct folding of PhoA* can be
achieved in vivo in the complete absence of any disulfide
bond isomerase activity. We plated cells lacking dsbC and
dsbG and expressing PhoA* onMOPS-XP plates with a filter
disc in the middle of the plates, which we spotted with 10ll
of 1 M dithiothreitol (DTT). This resulted in a gradient of
DTT away from the center of the filter disc. Surrounding the
disc was a zone of inhibition where the concentration of DTT
was too high to permit growth. However, immediately sur-
rounding the zone of inhibition was a blue halo of cells with
active correctly folded PhoA* (Supplementary Fig. S8). This
result indicates that PhoA* can indeed fold correctly in the
presence of DsbA and a chemical reductant, in the absence of
any known disulfide bond isomerase. Analogously, the
DsbC-dependent PDI detector can also form correct disulfide
bonds and fold into its native state, in the absence of DsbC
when supplemented with DTT (28). These observations
support the model that cycles of oxidation/reduction can re-
sult in correct formation of disulfide bonds.
A number of our DsbG* variants confer resistance to copper
overoxidation, in some cases up to the level seen for wt DsbC,
which can function as an efficient reductase in vitro (50). DsbC
has recently been shown to reduce the periplasmic copper-
binding protein CueP in vivo (46). Similar to DsbG, DsbC is
also a sulfenic acid reductase and maintains the single cysteine
of the l-arabinose-binding protein AraF in its reduced state
(5). The multiple in vivo roles of thiol oxidoreductases are
apparently substrate dependent and can overlap. We favor a
model in which DsbC not only isomerizes disulfide bonds but
also reduces non-native disulfide bonds formed by copper
oxidation, permitting reoxidation into native disulfide bonds
by DsbA. Support for this model was shown in vivo by re-
placing the isomerization activity of DsbC by a dedicated re-
ductase, resulting in correct folding of mis-oxidized proteins
(38). Further support for the overlapping disulfide bond
isomerase/reductase/oxidase activities of DsbG was shown
through the in vivo oxidase activities of the DsbG* mutants
isolated in this screen (Supplementary Fig. S7).
Oxidoreductases have previously been implicated in be-
stowing protection against metal-induced stress, resulting in
their use in bioleaching processes (10). There is an intimate
relationship between bioleaching organisms and oxidoreduc-
tases, as homologs of DsbC/G are frequently found in organ-
isms resistant to metal-induced oxidative stress. For example,
the DsbG homolog from Acidithiobacillus ferrooxidans,
known for its capacity to grow in the presence of elevated
metal concentrations, has been shown refold scrambled
RNase A, unlike E. coli DsbG (48). Furthermore, a homolog
of DsbG*KQ (www.ncbi.nlm.nih.gov/protein/151283208?
report= fasta) having the critical substitutions identified for
both copper protection (K113N) and PhoA* isomerization
(Q214R) is present in the sp. Janthinobacterium marseille
HH01. J. marseille HH01 also encodes a remarkable number
of proteins involved in resistance to drugs and heavy metals.
Altogether, more than 2.4% of its genome is devoted to genes
linked to resistance mechanisms (17). Yet, wt E. coli can grow
efficiently at elevated levels of copper (9mM), while J. mar-
seille was shown to grow at a mere 0.6mM. Most recently,
DsbC from Salmonella enterica serovar typhimurium was
shown to maintain the periplasmic copper-binding protein
(CueP) in its reduced state (46). This recent finding not only
further supports the role of DsbC in protecting cells from
copper-induced toxicity but also shows that DsbC can indeed
have a disulfide bond reductase function in vivo.
We have demonstrated the utility of the PhoA* screen to
identify amino acid residues critical in modulating the ac-
tivity and substrate specificity of DsbG. This screen can also
be used to capture new protein-folding factors, chaperones,
and oxidoreductases from various genetic sources (e.g., from
genomic libraries isolated from highly oxidizing environ-
ments) or to select for enzymes with modified oxidoreductase
activities (e.g., for DsbA mutants with higher fidelity in
forming the correct disulfide bonds).
Materials and Methods
E. coli strains, plasmids
Bacterial strains and plasmids used in this work are de-
scribed in Supplementary Table S4 and were constructed
using standard molecular and genetic techniques (33).
Screening for DsbG* capable of folding PhoA*
on MOPS-XP plates
We utilized the plasmid pMER79-dsbG-flag to construct a
polymerase chain reaction (PCR) mutagenized library of
dsbG*s protein-coding region using error prone PCR (Gen-
Script). From the resulting library, we obtained random
transformants on LB-Amp plates and subjected them to DNA
sequencing. The majority of the plasmids (20/24) had inserts
and, on an average, three nucleotide mutations per kilobase
pair. Only the mature region of dsbG (devoid of its signal
sequence) was PCR mutagenized and its cloning into the
NcoI and XbaI (Cat. No. R3193 and R0145; NEB) restriction
sites of pMER79 (38) resulted in a 5¢ fusion to the SRP-
dependent signal peptide (MRVLLFLLLSLFMLPAFS) of
TorT protein (34) and a 3¢ fusion to the FLAG-tag epitope.
Converting the native signal sequence of DsbG to an SRP-
dependent one allowed us to circumvent mutations that may
alter the secretion of DsbG*. The carboxyl terminal flag tag
allowed us to probe the in vivo redox state of DsbG*, inde-
pendent of mutations that may alter the folding and immu-
noblot detection of DsbG*. Cells expressing periplasmic
PhoA and grown on LB agar supplemented with XP can
hydrolyze the phosphate moiety in XP, resulting in blue
colonies (3). We used this enzymatic activity to develop a
MOPS-XP-based screen, where XP was the sole phosphate
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source. Thus, cells expressing active PhoA* can hydrolyze the
phosphate moiety from XP, permitting growth. We trans-
formed MB2272 strains carrying pBAD33-PhoA* with the
plasmid library of mutagenized dsbG* (pMER79-DsbG*-flag)
and plated them on MOPS-XP selective media (1.5% agar,
1·MOPS [Cat. No. M2101; Teknova], 0.2% glycerol, 5lM
IPTG, 0.2% l-arabinose [Cat. No. A3256; Sigma], 2mM
l-glutathione reduced [GSH, Cat. No. G4251; Sigma], ampi-
cillin [100lg/ml], chloramphenicol [10lg/ml], and 0.04mg/
ml XP [Cat. No. B6149; Sigma]), where XP was the sole
phosphate source. Thus, strains expressing mutant DsbG*
capable of folding PhoA* are able to hydrolyze the phosphate
from XP, resulting in large blue colonies after 2 days at 30C.
In vivo PhoA* activity assay
The PhoA* activity was determined in vivo by measuring
the rate of pNPP hydrolysis. PhoA*, when correctly folded,
hydrolyzes pNPP, leading to the formation of a yellow color
that can be detected at 410 nm. Cells expressing PhoA* for
*18 h were grown at 30C in minimal M63 media [3 g/L
KH2PO4, 5.25 g/L K2HPO4, 1 g/L (NH4)2SO4, 0.5 lg/L
FeSO4, 17 lg/ml 1 ·B1, and 1mM MgSO4] supplemented
with 0.2% glycerol, 5 lM IPTG, 0.2% l-arabinose, and the
selective antibiotics (ampicillin [100lg/ml], chlorampheni-
col [10lg/ml]). OD600 of the samples measured and stan-
dardized to 0.4. Twenty microliters of cells was mixed with
180 ll of the assay buffer (25mM pNPP [Cat. No. N4645;
Sigma], 1mM zinc acetate in a 100mM Tris buffer pH8) and
the assay was performed in 96-well microtiter plates, mea-
suring the rate of pNPP hydrolysis at 410 nm every 30 s for
2 h at 37C. PhoA* enzymatic activity corresponds to the
initial linear slope (Vmax) calculated after 2 h. The experi-
ments were conducted in duplicate, using two different bio-
logical samples.
In vivo RNase I activity assay
The RNase I activity was determined by measuring the rate
of RNA hydrolysis in a methylene blue assay (9). Methylene
blue intercalates into high-molecular-weight RNA, forming a
complex that absorbs at 688 nm. When correctly folded,
RNase I is active and hydrolyzes RNAmolecules resulting in
a decrease in absorbance at 688 nm. Cells expressing peri-
plasmic RNase I were grown and induced overnight at 30C
in rich media supplemented with 0.2% l-arabinose, 5 lM
IPTG, and the necessary antibiotics (ampicillin [100lg/ml],
chloramphenicol [10lg/ml]). Cells were harvested, re-
suspended in MOPS media (Cat. No. M2101; Teknova), and
sonicated. Using a Bradford assay, soluble protein concen-
trations of the samples were determined and standardized to
OD595= 0.3. Fifty microliters of samples was diluted to 1/100
with 150ll of the assay buffer (methylene blue 1 g/L, yeast
RNA 1 g/L [Cat. No. AM7118; Ambion], in 1 ·MOPS me-
dia), which had been preincubated for 10min in the dark at
25C. Change in absorbance at 688 nm was followed as a
function of time at 25C. Measured RNase I activity is the
initial velocity determined after 300 s of reaction.
Copper toxicity rescue
Cells expressing dsbC/dsbG/dsbG* from the plasmid
pMER79 were grown inM63media supplemented with 0.2%
glycerol, the necessary antibiotics (100 lg/ml ampicillin,
10 lg/ml chloramphenicol), and 5lM IPTG to mid-log phase
and standardized to OD600 = 0.4. After diluting the samples
from 100 to 10-4, 5 ll of cells was spotted on BHI plates
(52 g/L BHI, Cat. No. 211065; Becton, Dickinson and
Company) supplemented with 2% agar, 100lg/ml ampicil-
lin, 10 lg/ml chloramphenicol, and 9mM CuSO4. After 2
days of incubation at 30C, growth in the presence of copper
was observed for some of the mutants.
DsbG CXXC active site redox state analysis
Cells expressing wt dsbG or mutant dsbG*s were grown in
minimal M63 media supplemented with 0.2% glycerol, the
necessary antibiotics (100lg/ml ampicillin, 10lg/ml chlor-
amphenicol), and 5 lM IPTG. Onemilliliter cells OD600 = 0.5
were precipitated by incubating them with 50ll of 100%
trichloroacetic acid (TCA, Cat. No. A322-500; Thermo
Fisher Scientific) on ice for 20min. After pelleting the pro-
teins at 14,000 rpm for 10min, the proteins were washed with
500 ll ice-cold acetone for 20min to remove excess TCA.
Protein precipitate was spun for 10min at 14,000 rpm and
then air-dried at room temperature for 10min. The pellet was
resuspended in a 80 ll 4-acetamido-4¢-maleimidylstilbene-
2,2¢-disulfonic acid (AMS) buffer (15mM AMS [Cat. No.
A485; Invitrogen], 1% sodium dodecyl sulfate (SDS), and
100mM Tris HCl pH 8.0) using a shaker for 20min at room
temperature, followed by an incubation at 37C for 40min.
To identify the oxidized and reduced states of DsbG, two
controls were performed: (i) oxidized DsbG: the TCA pre-
cipitated pellet was resuspended in 80ll of buffer without
AMS (1% SDS, 100mM Tris HCl pH 8.0) (ii) reduced DsbG:
the TCA precipitated pellet was resuspended initially in a
200 ll DTT buffer (100mM DTT [Cat. No. B7705; NEB],
1% SDS, 100mM Tris HCl pH 8.0) for 20min at room
temperature under agitation. To the dissolved pellet, 600ll
minimal M63 media was added followed by TCA precipi-
tation and AMS alkylation. A loading buffer (Cat. No.
B7703; NEB) was added to the samples and boiled at 100C
for 10min. Three microliter samples were loaded on a 10–
20% SDS-PAGE tris-glycine polyacrylamide gel (Cat. No.
414893; CosmoBio). The gel was run for 75min at 30 mA/
gel. Proteins were transferred to a PVDFmembrane (Cat. No.
IPFL00010; Millipore). The blot was probed with rabbit
polyclonal anti-FLAG antibodies (Cat. No. 2044S; Cell
Signaling Technology) and detected using a secondary anti-
body coupled to an infrared dye (goat anti-rabbit IR Dye
800CW, Cat. No. 926-32211; Li-Cor).
Purification of DsbG, DsbC, and DsbG*s
DsbC, DsbG, and DsbG*s were purified using the pMAL
protein fusion and expression system (Cat. No. E8200; NEB).
A sequence encoding four alanines was inserted between
malE and dsbC/G/G* in the pMAL-c5X vector, as previous
experiments with MBP-DsbC/DsbG/DsbG* showed that
these fusions were resistant to cleavage with factor Xa. 3L of
T7 Express Competent E. coli (Cat. No. C2566; NEB) con-
taining the pMAL-c5X-dsbC/G/G* were grown at 37C in
rich media (5 g/L yeast extract, 10 g/L tryptone, 5 g/L sodium
chloride, and 2ml sodium hydroxide pH 7.2) supplemented
with 0.2% glucose and the selective antibiotic (ampicillin
100mg/ml). At OD600= 0.5, MBP-DsbC/G/G* expression
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was induced with 0.3mM IPTG for 2 h at 37C. Cells were
harvested by centrifugation, resuspended in a 75ml column
buffer (CB) (20mM Tris-HCl pH 7.4, 0.2 M NaCl, 1mM
ethylenediaminetetraacetic acid [EDTA]), and frozen at
-20C overnight. The cell suspension was thawed, lysed by
sonication, and centrifuged to obtain the soluble fraction. The
crude extract was diluted 1:6 with CB. The crude fraction was
applied to a 5 · 2-cm column containing 40ml amylose resin
(Cat. No. E8021; NEB). The column was washed with 250ml
CB, and the MBP-DsbC/G/G* fusion protein was eluted with
250ml water. Using a Vivaspin 30 concentrator (Cat. No.
VS2022; Sartorius), the eluted protein was concentrated to
*1mg/ml by ultrafiltration using the Vivaspin 30 concen-
trator (Cat. No. VS2022; Sartorius). A Factor Xa buffer was
added to a final concentration of 20mM Tris-HCl pH 8,
100mM NaCl, 0.2mM CaCl2, and the fusion protein was
digested at room temperature for 24 h with 1% factor Xa (Cat.
No. P8010; NEB). The cleavage mixture was loaded on the
same amylose column used for the first step. The flow-
through was collected and run through a HiTrap benzamidine
FF column (Cat. No. 17-5143-01; GE Healthcare). The col-
umn flow-through was concentrated to 5mg/ml, dialyzed into
a 10mM HEPES buffer pH 7.5, and stored at -20C.
In vitro oxidoreductase assays
Disulfide bond reductase assay. The two polypeptides of
insulin (A and B) are covalently linked by a disulfide bond.
The reduction of insulin results in the precipitation of the
protein, which can be monitored in a spectrophotometer. The
ability of DsbC, DsbG, and variants to catalyze the reduction
of human insulin in the presence of DTT was tested as de-
scribed previously (16). A stock solution of 872 lM insulin
was freshly prepared in a 0.1 M Tris buffer, pH *7.0, and
1mM EDTA before each assay. The reaction mixtures were
prepared directly in cuvettes using a 0.1 M sodium phosphate
buffer, pH 7.0, 1mM EDTA, and 0.33mM DTT with 10lM
enzyme in a final volume of 0.75ml. Adding insulin to a final
concentration of 131lM started the reactions. After thor-
oughly mixing, the cuvettes were placed in the spectropho-
tometer and measurements were performed at 650 nm for
120min. In all experiments, the uncatalyzed reduction of
insulin by DTT was monitored in a control reaction without
the addition of enzymes.
Disulfide bond oxidase assay. The oxidative folding of
hirudin was tested as described previously (27). In brief, the
oxidase activity was determined by the rate at which 0.5lM
oxidized DsbG or variants donate a disulfide bond to reduced
hirudin (ranging from 1 to 2.5lM). The buffer was nitrogen
saturated. The fluorescence excitation at 295 nm increases when
oxidized DsbG or DsbG* loses its active site disulfide bond;
however, hirudin itself shows no fluorescence change during the
reaction. The assay was performed on a Hitachi F-4500 fluo-
rescence spectrophotometer in the single-mixing mode. The
traces were fit individually to a single exponential equation to
obtain the pseudofirst-order rate constant Kobs. Averaged Kobs
values were plotted against the hirudin concentration. The slope
is the observed second-order rate constant of the reaction.
Disulfide bond isomerase assay. The scrambled hirudin
refolding assay was conducted as described previously (23).
Hirudin (Botai Ltd.) samples were diluted to 24 lM and in-
cubated with or without 24lM reduced DsbC, DsbG, or
DsbG variants in 100mM sodium phosphate, 1mM EDTA,
pH 7.0. Following incubation at room temperature at various
time points, folding reactions were quenched by addition of
10% (v/v) formic acid. Buffer was nitrogen saturated. The
reaction products were separated by reverse-phase HPLC on
a VydacTM218TP54 C18 column at 55C using an aceto-
nitrile gradient (19–25%, 30ml) in 0.1% (v/v) trifluoroacetic
acid. The eluted proteins were detected by their absorbance at
220 nm. The activity was quantified by the ratio of native
folded hirudin peak area versus all hirudin peaks after the
reaction quenched at 17 h. The ratio of DsbC catalyzed re-
action was set to 100%, while all DsbG* catalyzed reactions
were normalized to wt DsbC to represent the DsbG*isome-
rase activity. Noncatalyzed reaction was used as the negative
control.
Bioinformatic analysis of DsbC and DsbG homologs
Using 11 DsbC and 20 DsbG homologs with 99–100% se-
quence identity to E. coli DsbC and DsbG, homologs were
selected fromBLAST results. The homologswere aligned using
ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2/). The align-
ments were used to generate two hidden Markov models using
Hmmer3’s hmmbuild function (http://hmmer.janelia.org).
Hmmer3’s hmmsearch function was used to search for proteins
within a database of 816 bacterial and archaeal genomes
downloaded on March 14, 2009, from NCBI (ftp://ftp.
ncbi.nlm.nih.gov/genbank/genomes/Bacteria/) that match the
models with a sequence E-value threshold £1e-05. The mat-
ched sequences were aligned with muscle (www.ebi.ac.uk/
Tools/msa/muscle/) and trimmed to remove poorly aligned re-
gions. Two methods, trimAL (http://trimal.cgenomics.org)
and Gblocks (http://molevol.cmima.csic.es/castresana/Gblocks.
html), produced similar results. A tree was generated using
PhyML (www.atgc-montpellier.fr/phyml/). Prediction of pro-
tein topology using Phobius (http://phobius.binf.ku.dk) and
conserved residues of DsbC andDsbG homologs usingConSurf
(http://consurftest.tau.ac.il) were performed. Finally, the tree
was visualized using iTol (http://itol.embl.de). Alignment of
DsbC andDsbGwas performedby theCEAlign tool in PyMOL,
based on the combinatorial extension algorithm (37).
Homology modeling of DsbG mutants. DsbG K113N,
Q214R, V199A, and KQ mutants were modeled from DsbG
crystal structure (PDB 1V57) (11) using Modeler 9.13 (32), as
described in the Modeler tutorial (basic modeling). Fifty ho-
mologymodels were built and the best were selected. Residues
of the thioredoxin domain (88–230) were selected for further
refinement. Minimization: protein solvation and minimization
steps were performed using the Molecular Modeling ToolKit
(MMTK) (15). Step 1: Protonation/Protonation state of
homology models was set at pH 7, according to the standard
setting in MMTK. Next steps were run on the reduced form of
the thioredoxin domain. Step 2: Solvation/Homology mod-
els were loaded into orthorhombic periodic boxes twofold
larger than model eigenvalues. Model coordinates were fixed
to prevent model deformation during the solvation process.
Explicit water molecules were randomly added to reach a
density of 1 g/cm3, without molecules overlapping. Using the
Amber99 force field (43), the solventwas equilibrated for 1000
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steps at 300 K and 1 atm. Lenard jones (LJ) and electrostatic
(El) cutoffs were set to 7 A˚ and 4 A˚, respectively. The solvent
was minimized around homology models until a convergence
of 5e-3, using a steepest descent minimization. Step 3: Mini-
mization/Homology model coordinates were unfixed. LJ
cutoff was set to 10 A˚, and El cutoff was computed using
Ewald summation. Both solvent and homology models were
minimized until a convergence of 5e-3, using a conjugate
gradient minimization.
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Abbreviations Used
AMS¼ 4-acetamido-4¢-maleimidylstilbene-
2,2¢-disulfonic acid
BHI¼ brain heart infusion
CB¼ column buffer
DTT¼ dithiothreitol
EDTA¼ ethylenediaminetetraacetic acid
GSH¼ l-glutathione reduced
HPLC¼ high-performance liquid
chromatography
LJ¼Lenard jones
MOPS¼ 3-(N-morpholino)propanesulfonic acid
PCR¼ polymerase chain reaction
pNPP¼ 4-nitrophenyl phosphate
PVDF¼ polyvinylidene fluoride
RNase I¼ ribonuclease I
SDS¼ sodium dodecyl sulfate
SDS-PAGE¼ sodium dodecyl sulfate–polyacrylamide
gel electrophoresis
SRP¼ signal recognition particle
TCA¼ trichloroacetic acid
wt¼wild type
XP¼ 5-bromo-4-chloro-3-indolyl phosphate
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